Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
thevid...thank you
Related info - Not sure if this gas already been posted apologies if it has.
Evolution of SARS-CoV-2 Shedding in Exhaled Breath Aerosols
https://www.medrxiv.org/content/10.1101/2022.07.27.22278121v1
These findings provide additional evidence that inhalation of infectious aerosols is the dominant mode of transmission and emphasize the importance of ventilation, filtration, and air disinfection to mitigate the pandemic and protect vulnerable populations. We anticipate that monitoring aerosol shedding from new SARS-CoV-2 variants and emerging pathogens will be an important component of future threat assessments and will help guide interventions to prevent transmission via inhalation exposure.
@bella
I had email reply on this question and was told still working with both companies.
Modern Water and Microsaic at the The World Water Week in Stockholm: 23 August to 1 September 2022
https://worldwaterweek.org/news/join-us-for-world-water-week-2022
https://www.linkedin.com/feed/?trk=homepage-basic_signin-form_submit
Courtesy of https://www.linkedin.com/posts/modern-water-plc_wwweek-water-climatechange-activity-6964860739924717568-mWrv?utm_source=linkedin_share&utm_medium=member_desktop_web
ATB
Thank you Gerry.
Regarding the BT, based on recent RNSs etc have you completely moved away from using any Avacta affimers?
Ditto, many thanks Gerry.
Thanks for taking the time Gerry.
I have been less inclined to respond to opinion on the BB but sometimes it is important to fine tune those who do take the time and effort to post and I appreciate reading them.
I wish to point out the reference to Breath Test and timeline.
If you look at the Tax Credits in the 2021 Annual Report on page 43 you will see that R&D tax credits are £711,000 compared to £77,000 for the year 2020.
As the UK offers 33% tax credits, it is easy to calculate the investment by the Company in R&D in both the Microbiome and Modern Water equipment, Wich includes both the PD for water contamination and BT for the multiplex biomarker detection, of which SARS-CoV-2 is but one target pathogen. This is a digital health medical device and rolling it out for a single biomarker is not viable when it is to be used in a clinical diagnostic laboratory or eventually small enough to be used in an GP office.
That is nearly 10 times what was spent in R&D in 2020 Some of that is on BT. Progress is being made and while it may not be detecting COVID in test centers we are falling behind on delivery taking into account the time it takes to bring a medical device to market.
As a shareholder I am as frustrated as any shareholder, but the Company is growing at the pace it can considering the demands on products, equipment and services demanded in all the fast growth areas we operate in.
Hopefully justifiably (Character count lied to me)...
Since character count forced a second post I'll add below. Nothing new, familiar to regulars. But if we have any new readers (We don't just trust company on faith alone...):
Wednesday 6 October 2021, 18:00 - 19:20
Data Bites #23: getting things done with data in government
Andrew Engeli, Deputy Director for Environmental Monitoring for Health Protection at the UK Health Security Agency, on the challenges of developing novel data sources in the context of the pandemic response
https://youtu.be/p6gIvh3Z6r0?t=2067
Q&A:
https://youtu.be/p6gIvh3Z6r0?t=2579
Wastewater monitoring during and
after a pandemic
Perspectives from the Environmental Monitoring for Health Protection programme
Dr Matthew Wade, Lead Scientist: Wastewater R&D, Environmental Monitoring for Health Protection
https://www.swig.org.uk/wp-content/uploads/2021/10/Matthew-Wade-2022.pdf
29 March 2022
Aqua Enviro WBE Conference Michael Dooley Presentation
Strathkelvin Instrument's Managing Director, Michael Dooley, presents Strathkelvin's enormous breakthroughs in innovation in the world of Wastewater Based Epidemology - sampling straight from the wastewater treatment plant to an automated qPCR robot - producing Covid-19 results in the local population in under an hour. A huge leap forward in capability for National & International Public Health, the same system being able to be used for Influenza, measles etc
https://m.youtube.com/watch?v=cKhSEIvdMAQ
Disagree that it's just market sentiment. Share price is in no small part a result of the failure of the company to deliver to timetables indicated and to satisfactorily update when delays occur. Issues exacerbated when company websites lack information... Any potential investor going to Modern Water site looking a listing for PD will end up empty handed (Investor Meet Q41). Likewise looking at BT site will be less than impressed. Small step from not impressed to not invested.
Investor Meet answer to Q20 (Can you please give some update on microtox BT):
The breath test is one extra step along the Microtox PD as to how we extract a sample. The Microtox PD remains part of the development process for miniaturisation, and we have provided updates on both improvements and installations where the PD units are. Once we are satisfied with the final project, we will apply for medical device classification, as it requires such application based on the final device that would be used for a single persons diagnosis. It remains a well advanced, but not yet public, development
###
And that's your lot...
Q36: RNS Number : 4721S, 17 March 2021, set out data requirements for Target Product Profile for Microtox BT. Can you confirm all necessary data have been successfully collected?
This was answered in Question 20
Q37: RNS Number : 2004V, 10 December 2021 advised "roll out of the breath test is subject to meeting the satisfactory requirements of EU Regulatory approvals which will be carried out on the latest version of the Microtox® BT units. Further information on this will be provided in H1 2022." To date has the company contracted a notified body to achieve CE marking? If yes when was this undertaken and what is the current expectation for the timeline for completion of approvals?
This was answered in Question 20
Q38: When is it anticipated that investors will first be shown Microtox BT? To date unit including PBM-HALE has not been shown. What plans do the company have for the microtoxbt.com domain?
This was answered in Question 20
##
The answer to Q20 does not address subsequent questions and the failure of company to address requested detail is unhelpful.
A failure to address data collection, despite RNS 4721S which noted " Additional supervised breath test clinical trials from a larger group is expected to provide sufficient data to meet the desired and acceptable criteria in the TPP to roll out the COVID19 and other pathogen breath tests later this year."
For those keeping score the above mentioned "this year" is 2021...
The plans of p23 of below document not mentioned again:
www.deepverge.com/wp-content/uploads/2020/12/DeepVerge-UK-Investor-December-2020.pdf
A failure to address how regulatory approvals for latest version of BT (RNS 2004V) becomes some future version. No revised timeline.
A failure to address the BT website.
'course the company acts as it does knowing what it knows... Hop
Hi Dwatchorn, it's refreshing to read a carefully considered post for a change.
I too am a longish term holder of DVRG and have closely followed the substantial progress of the company.
My rational for investing in DVRG is similar to yours in that the macro environment in which it operates in has substantial tail-winds currently. Water shortages, water monitoring in real time and the monitoring and detection of pathogens in water and sewage are becoming increasingly major global issues which will only become larger and more problematic with climate change. Hence DVRG is in the right place at the right time. DVRG is managed by GB who has a track record of entrepreneurial success , is passionate about making a difference to global environmental issues and is a human workhorse. He is also extremely engaging with shareholders (I know to the annoyance of some shareholders), however in my mind it reflects his exuberance and passion for what he does and desire to share that passion with shareholders. Too many CEOs take a back seat approach and barely engage with shareholders at all.
The poor share price is merely due to poor sentiment in the market generally. If you look at other well managed AIM companies many are currently trading on approximately 1x or even less than 1x revenue, e.g. ORPH, EAAS, SAL.
The sp will eventually recover when sentiment improves. The main thing is that Gerry is growing the company substantially. Triple digit revenue growth for 3 successive years during 2 years of a pandemic is no mean feat.
The environmental health division is also well diversified geographically which minimises geopolitical risks.
And then of course we have the life sciences division of labskin and STC. STC we know is growing at a phenomenal rate, and the revenue projections for 2022 for DVRG don't even include STC revenue! In STC so far we are seeing only the tip of the iceberg. The unique skin microbiome database is extremely sought after and valuable and in the next few weeks we will find out what plans Gerry has to maximise shareholder value from it. What we do know is that there are many potential revenue streams for STC.
All my opinion of course and please do your own research.
I am a long(ish) term holder here (3yrs+) and am currently about 20% down on my (5 figure £) holding.
I love the work the company undertakes and am continually amazed that the investing world is not all over DVRG as a future winner across several differing industries. Our market cap. proves this!
I don't pretend to fully understand the intricacies of the company's finances and appreciate that the share price reflects the 'experts' views on risk and reward. I have invested based on my amateur gut instinct of the future of the industries we operate in rather than in depth financial knowledge (not what an investing professional would do, I know, and probably a factor of my losses!).
I appreciate the interaction Gerry has with us via Twitter and enjoy the comments from the other regular contributors over there and on here. They have been a factor in several top-ups! (again, I know, not a good idea).
My hope is that surely with all that is happening in the world regarding covid, contamination detection, sewage problems, climate change and specifically water based issues at present, we are perfectly placed to be snapping up major contracts to help companies and countries all over the world through our Modern Water division. The constant stream of drought headlines we all see and that Gerry posts about on Twitter can only back up the benefits of Modern Water's services. This is obviously Gerry's reason for doing so. Of course a huge amount of work is going on across all divisions that we know nothing about until we get the RNSs. How long until the MW government contract that we are all waiting for, or a major STC or Labskin development?
I am tempted daily to top up my holding (and did so recently at 11p) but then wait another day as there does not seem to be any major buying from the big institutions that must know what they're doing (so we are led to believe). What am I missing? Gut instinct and the risk taker in me says Deepverge will be a long term winner and that the current share price is a huge opportunity but then common sense and the fear of over committing holds me back. After all, what do I know? The share price is where it is for a reason, isn't it? A common dilema for many on here I'm sure! We all want to be the clever one who bought low before the big contract RNS drops, not the idiot who bought before the profit warning!
I'm very happy to hold, (and will no doubt top up again soon) and just wanted to put my thoughts down. Good luck to all other holders and keep up the good work Gerry and the team.